Ascendis’ impairments of R4.2bn a bitter pill to swallow
Ascendis has been a terrible investment, and now everything hinges on the sale of its crown jewel
02 December 2019 - 12:00
Pharmaceuticals and healthcare business Ascendis has not had a good year. In fact, it does not have a good three-or five-year history.
The business, which listed on the JSE in November 2013, was bankrolled by well-known private equity team Coast2Coast, which, aside from being a material shareholder in Ascendis, also drove the highly ambitious acquisition strategy...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.